Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration
Sangamo Therapeutics' stock dropped sharply after Pfizer announced it is ending their collaboration on a groundbreaking hemophilia drug. Discover the impact on biotech stocks.
Topic
Pfizer
A collection of 20 issues
Pfizer Increases Prices on Over 60 Drugs, Including Paxlovid
Pfizer has announced price hikes on more than 60 drugs, with a notable 3% increase on its antiviral treatment, Paxlovid. Explore the full details here.
Pfizer Increases Prices on Over 60 Drugs, Including Paxlovid
Pfizer raises drug prices, impacting over 60 medications such as Paxlovid. Explore how this price hike could affect the pharmaceutical market and consumers.
Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy
Pfizer terminates its partnership with Sangamo, citing limited interest in advancing another hemophilia A gene therapy. Explore the implications for biotech innovation.
Sangamo Stock Drops 67% After Pfizer Partnership Ends
Sangamo Therapeutics' shares nosedived by 67% following Pfizer's decision to terminate their hemophilia A gene therapy collaboration. Explore the impact on biotech stocks.
Pfizer's Withdrawal Hits Sangamo with Negative Sentiment
Explore the impact of Pfizer's withdrawal on Sangamo, leading to negative market sentiment. Key insights into biotech market dynamics.
Pfizer Opts Out of New Hemophilia A Gene Therapy
Pfizer pulls back on developing a new gene therapy for hemophilia A, citing limited market interest. Explore the implications for the hemophilia community and biotech sector.
Pfizer Alters Timeline for Drug Approval Plans
Pfizer changes plans for US and European drug approval, initially set for early 2025. Explore the implications of this strategic shift.
Sangamo Therapeutics Stock Plummets 67% After Pfizer Ends Hemophilia A Partnership
Sangamo Therapeutics Inc. stock dropped 67% as Pfizer Inc. terminated its collaboration on gene therapy for hemophilia A, impacting Sangamo's financial outlook.
Sangamo Shares Plunge After Pfizer Ends Gene Therapy Deal
Sangamo stock drops sharply as Pfizer terminates collaboration on hemophilia A gene therapy. Explore the impact on Sangamo's market position and future plans.